Mineralcorticoid receptor antagonists for the treatment of...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/00 (2006.01) A61K 31/585 (2006.01) A61P 15/00 (2006.01)

Patent

CA 2679520

The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endometriosis, which has a more favorable effectiveness profile and/or profile of side effects than previously available treatment therapies. With a mineralcorticoid receptor antagonist, endometriosis can be lastingly treated without resulting in a loss of bone mass.

L'invention a pour objet l'utilisation d'antagonistes du récepteur de minéralocorticoïde pour la production d'un médicament servant au traitement de l'endométriose. L'invention concerne en particulier un agent thérapeutique amélioré contre l'endométriose présentant un profil efficacité/effet secondaire plus avantageux que les thérapies de traitement dont on dispose jusqu'à présent. Grâce à un antagoniste du récepteur de minéralocorticoïde, l'endométriose peut être traitée de façon durable sans entraîner de perte de la masse osseuse.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Mineralcorticoid receptor antagonists for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mineralcorticoid receptor antagonists for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mineralcorticoid receptor antagonists for the treatment of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2069043

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.